Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14, 374.

Author(s): Simon Bailey (corresponding author) [1,2,*,†]; Nicolas André [3,4,†]; Lorenza Gandola [5,†]; Maura Massimino [6,‡]; Keith Wheatley [7]; Simon Gates [7]; Victoria Homer [7]; Stefan Rutkowski [8,‡]; Steven C. Clifford [2,‡]

Missing Funding

In the original publication [1], the funder Cancer Research UK, A2524 was not included.

Addition of Authors

Keith Wheatley, Simon Gates, and Victoria Homer were not included as authors in the original publication. The reason we would like to add the authors is that the statistical element of the trial and the trial design were in a large part done by the statistical authors and the team were necessary for the running of the trial. The corrected Author Contributions Statement appears here.

Author Contributions: Conceptualization, S.B., N.A., L.G., M.M., K.W., S.R. and S.C.C.; methodology, K.W., S.G. and V.H.; project administration, S.G. and V.H.; resources, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—original draft preparation, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—review and editing, S.B., N.A., L.G., M.M., S.R. and S.C.C. All authors have read and agreed to the published version of the manuscript.

Additional Affiliation

Cancer Research UK Clinical Trials Unit, University of Birimingham, Birmingham B15 2TT, UK; [email protected](K.W.); [email protected] (S.G.); [email protected] (V.H.)

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Reference

1. S. Bailey; N. André; L. Gandola; M. Massimino; S. Rutkowski; S.C. Clifford Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial., 2022, 14, 374. DOI: https://doi.org/10.3390/cancers14020374. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35053536.

Author Affiliation(s):

[1] Great North Children’s Hospital, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK

[2] Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK; [email protected]

[3] Pediatric Hematology and Oncology Department, Hôpital Pour Enfants de La Timone, AP-HM, 13005 Marseille, France; [email protected]

[4] Centre de Recherche en Cancérologie de Marseille, SMARTc Unit, Inserm U1068, Aix Marseille University, 13005 Marseille, France

[5] Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; [email protected]

[6] Pediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; [email protected]

[7] Cancer Research UK Clinical Trials Unit, University of Birimingham, Birmingham B15 2TT, UK; [email protected] (K.W.); [email protected] (S.G.); [email protected] (V.H.)

[8] Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected]

Author Note(s):

[*] Correspondence: [email protected]; Tel.: +44-1912824068

DOI: 10.3390/cancers16061084

Article Details

Printer friendly Cite/link Email Feedback
Author:	Bailey, Simon; André, Nicolas; Gandola, Lorenza; Massimino, Maura; Wheatley, Keith; Gates, Simon; Ho
Publication:	Cancers
Geographic Code:	4EUUK
Date:	Mar 1, 2024
Words:	463
Previous Article:	Characteristics of Cancer Stem Cells and Their Potential Role in Endometrial Cancer.
Next Article:	Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to...
Topics:	Cancer Gliomas